ViroXis Corporation is a bio-pharmaceutical company based in San Antonio, Texas, specializing in the development and commercialization of botanical pharmaceuticals derived from East Indian sandalwood oil. The company has developed a proprietary botanical ointment that utilizes a defined mixture from Santalum album, aimed at treating human papillomavirus (HPV) infections of the skin in both children and adults. Additionally, ViroXis is working on an EISO cream to address other HPV-related conditions. The company has established strategic partnerships with TFS Corporation Ltd. and DPT Laboratories, Inc. Founded in 2006, ViroXis operates as a subsidiary of TFS Corporation Ltd. as of 2015.
PNP Therapeutics is an early-stage, biopharmaceutical company engaged in the development of a platform technology and proprietary products for the treatment of cancer. At the center of PNP's Therapeutic System is a patented enzyme (E. coli purine nucleoside phosphorylase) that has been shown to work with a variety of well-characterized nucleoside prodrugs generating active metabolites with high levels of anti-tumor activity.
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.